RxDoctor Payments Data

Brandon Miner, DO

MOHS-Micrographic Surgery · Idaho Falls, IDNPI 1528279189

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 28.8% of the total. Reporting peaked in 2019 at $1,290 and has fallen 71.4% since, to $369 in 2025.

$5,235in general payments, 2019–2025

Across 247 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$739
  • Regeneron$526
  • Johnson & Johnson$365
  • Sanofi$302
  • UCB, Inc.$257
  • plus $2K from 17 others
$140,644in research payments, 2019–2025

Across 33 payments — averaging $4261.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$141K

What the payments were for

  • Food & beverage$5,03596%
  • Education$2004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$444,599
Medicare patients
753
Services billed
6,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$56,897
Fluorouracil42$4,646
Clobetasol Propionate39$1,666
Metronidazole16$989
Triamcinolone Acetonide79$836
Cephalexin158$806
Clindamycin Phosphate18$796
Betamethasone Dipropionate12$388
Mupirocin61$357
Ketoconazole23$351
ValacyclovirValacyclovir Hcl18$348
Minoxidil11$21

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →